AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30288156
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of individual tablets (gemigliptin 50 mg and metformin XR 1,000 mg)
Trial: 27650124
Drug: ω‐3 polyunsaturated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 polyunsaturated fatty acids (PUFAs) treatment for 12 weeks
Trial: 25379431
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine (ATX) administration
Trial: 20088695
Drug: 12-week treatment
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week treatment
Trial: 16956917
Drug: 24-week treatment
RxNorm normalized name: Weeks and Leo Complete Lice Treatment KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-week treatment
Trial: 20088695
Drug: Suboptimal drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suboptimal drug concentrations
Trial: 18852484
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of Ascorbic Acid (AA)
Trial: 18852484
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of iron carbonyl
Trial: 18852484
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of Ascorbic Acid (AA) plus 150 mg of iron carbonyl
Trial: 15733070
Drug: High-dose glucose-insulin-potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose glucose-insulin-potassium (GIK) treatment for 24 hours
Trial: 15733070
Drug: High-dose glucose-insulin-potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose glucose-insulin-potassium (GIK) treatment
Trial: 10664047
Drug: Latanoprost, 0.005%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost, 0.005% once daily
Trial: 10664047
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of timolol, 0.5% twice daily, and dorzolamide, 2% twice daily
Trial: 1539069
Drug: Acetaminophen (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (0, 325, 650, 1300 or 1950 mg)
Trial: 1539069
Drug: Ethanol (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (total dose = 0.625 g/kg; five divided doses)
Trial: 24842476
Drug: CZP 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CZP 200 mg and methotrexate (J-RAPID trial)
Trial: 24842476
Drug: CZP 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CZP 200 mg alone or with disease-modifying agents other than methotrexate (HIKARI trial)
Trial: 19179968
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alfa-2b monotherapy
Trial: 17517832
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alfa-2b plus lamivudine combination therapy
Trial: 11481357
Drug: ADocT (doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADocT (doxorubicin 50 mg/m2 and docetaxel 75 mg/m2 with tamoxifen)
Trial: 11481357
Drug: ADoc (doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADoc (doxorubicin 50 mg/m2 and docetaxel 75 mg/m2 without tamoxifen)
Trial: 9707742
Drug: Azithromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (10 mg/kg in children or 500 mg/day in adults for 3 days)
Trial: 9707742
Drug: Amoxicillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanic acid (standard doses for 7 to 14 days)
Trial: 9707742
Drug: Cefaclor (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (standard doses for 7 to 14 days)
Trial: 3133266
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + Glibenclamide (15 mg per day)
Trial: 22590838
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + Placebo
Trial: 26042933
Drug: Lomustine single
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lomustine single agent
Trial: 26042933
Drug: Bevacizumab single
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab single agent
Trial: 12526280
Drug: Telmisartan 40-80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 40-80 mg
Trial: 16421476
Drug: Losartan 50-100
RxNorm normalized name: losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan 50-100 mg
Trial: 11320384
Drug: Melatonin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (2 mg)
Trial: 17462454
Drug: Antifibrinolytic drugs
RxNorm normalized name: ANTIFIBRINOLYTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifibrinolytic drugs
Trial: 29518295
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (1.0 ml) and injectable water (1.5 ml)
Trial: 29518295
Drug: Bupivacaine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (1 ml, 5 mg/ml) and injectable water (1.5 ml)
Trial: 17596110
Drug: Darunavir/r (400/100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/r (400/100mg twice daily)
Trial: 17596110
Drug: Atazanavir/r (300/100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/r (300/100mg once daily)
Trial: 17596110
Drug: Darunavir/r (400/100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/r (400/100mg twice daily) plus Atazanavir (300mg once daily)
Trial: 16334443
Drug: Antibiotic combination
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic combination therapy (amoxicillin, tetracycline, metronidazole) for 2 weeks
Trial: 346192
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy (Vinblastin 6 mg/m2, Thiotepa 6 mg/m2, Rufocromomycine 60 microgram/m2, Methotrexate 15 mg/m2, Procarbazine 30 mg/m2)
Trial: 346192
Drug: Intraarterial chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial chemotherapy (DTIC 80 mg/kg for ten days)
Trial: 24239156
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg/daily for 30 days
Trial: 24239156
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg/daily for 30 days
Trial: 24239156
Drug: Bergamot-derived polyphenolic
RxNorm normalized name: BERGAMOT
DrugBank: Bergamot oil (DB14335)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bergamot-derived polyphenolic fraction (BPF) 1000 mg/daily for 30 days
Trial: 24239156
Drug: BPF 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPF 1000 mg/daily plus rosuvastatin 10 mg/daily for 30 days
Trial: 18649820
Drug: Programmable medication
RxNorm normalized name: PUMP,LUTREPULSE PROGRAMMABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmable medication devices (dispensers and timers)
Trial: 15248415
Drug: Intravenous amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous amoxicillin plus clavulanic acid (2.2 g) administered 10 minutes before tonsillectomy
Trial: 15248415
Drug: Oral amoxicillin-clavulanic
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin-clavulanic acid (3 doses the day before surgery, plus one oral administration 2 hours before tonsillectomy)
Trial: 11086366
Drug: Stratified care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stratified care (n = 279) with aspirin 800 to 1000 mg plus metoclopramide 10 mg for MIDAS grade II and zolmitriptan 2.5 mg for MIDAS grade III and IV.
Trial: 11086366
Drug: Step care
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step care across attacks (n = 271) with initial treatment of aspirin 800 to 1000 mg plus metoclopramide 10 mg, switching to zolmitriptan 2.5 mg if not responding in at least 2 of the first 3 attacks.
Trial: 11086366
Drug: Step care
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step care within attacks (n = 285) with initial treatment of aspirin 800 to 1000 mg plus metoclopramide 20 mg, escalating to zolmitriptan 2.5 mg if not responding after 2 hours.
Trial: 8442969
Drug: Succinylcholine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 0.5 mg/kg after no pretreatment
Trial: 8442969
Drug: Succinylcholine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 0.5 mg/kg after d‐tubocurarine 0.05 mg/kg IV 3 minutes before
Trial: 8442969
Drug: Succinylcholine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 0.5 mg/kg after chlorpromazine 0.1 mg/kg IV 3 minutes before
Trial: 8442969
Drug: Succinylcholine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 0.5 mg/kg after alpha‐tocopherol (vitamin E) 600 mg in three divided doses orally at 6‐hour intervals
Trial: 8442969
Drug: Succinylcholine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 0.5 mg/kg after aspirin 600 mg orally 1 hour before
Trial: 31678224
Drug: Local consolidative
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local consolidative therapy (LCT)
Trial: 28549873
Drug: Topical Betadine
RxNorm normalized name: Betadine Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Betadine (Povidone‐iodine)
Trial: 28549873
Drug: Topical Clotrimazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Clotrimazole
Trial: 16515902
Drug: Heparin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin with protamine reversal
Trial: 14747047
Drug: Androgen blockade
RxNorm normalized name: Blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen blockade with 4 cycles of immediate chemotherapy
Trial: 14747047
Drug: Androgen blockade
RxNorm normalized name: Blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen blockade with delayed chemotherapy
Trial: 11109313
Drug: Transdermal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal hormone replacement therapy (HRT) with 17-beta-estradiol and noretisterone acetate, TTS for 3 months.
Trial: 3313739
Drug: Mefloquine 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine 750 mg, sulfadoxine 1500 mg and pyrimethamine 75 mg (MSP) single oral dose
Trial: 3313739
Drug: Quinine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (10 mg/kg tds X 7 days oral therapy)
Trial: 27327024
Drug: High-CHO (HCHO):
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-CHO (HCHO): 10 g·kg CHO, 2.5 g·kg protein, and 0.8 g·kg fat for the entire trial period
Trial: 27327024
Drug: Reduced-CHO but
RxNorm normalized name: trans-but-2-enedioic acid
DrugBank: Fumaric acid (DB01677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-CHO but high-fat availability (HFAT): 2.5 g·kg CHO, 2.5 g·kg protein, and 3.5 g·kg fat for the entire trial period
Trial: 24293578
Drug: 7.5 mg/day
RxNorm normalized name: nicotine 7.5 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg/day of prednisolone for 6 weeks
Trial: 18801638
Drug: Current therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current therapy for cardiac arrest (not specified as intervention or control)
Trial: 7867183
Drug: c7E3 Fab
RxNorm normalized name: aDabi-Fab
DrugBank: Idarucizumab (DB09264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: c7E3 Fab 0.25 mg/kg
Trial: 2026760
Drug: Insulin dose
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin dose 0.6 mU/kg‐min
Trial: 2026760
Drug: Insulin dose
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin dose 5.0 mU/kg‐min
Trial: 25828994
Drug: Concurrent anemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent anemia and inflammation (CRP ≥ 10 mg/L)
Trial: 23713032
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no drug) during PEI after leg cycling
Trial: 23713032
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no drug) during PEI after handgrip
Trial: 19351238
Drug: Ciclesonide therapy
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide therapy
Trial: 8098276
Drug: Denopamine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denopamine (20 mg)
Trial: 2957943
Drug: Intrahepatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrahepatic therapy (14-day continuous infusion of fluorodeoxyuridine at 0.3 mg/kg body weight per day)
Trial: 2957943
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy (14-day continuous infusion of fluorodeoxyuridine at 0.15 mg/kg body weight per day)
Trial: 2957943
Drug: Crossover from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover from systemic to intrahepatic therapy after tumor progression
Trial: 2957943
Drug: Intrahepatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrahepatic therapy
Trial: 28753030
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture and normal saline injections
Trial: 28753030
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with anti-parkinsonian drugs
Trial: 25678098
Drug: Finerenone (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finerenone (doses ranging from 2.5 to 20.0 mg once daily)
Trial: 25678098
Drug: Eplerenone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (25 mg every second day to 50 mg once daily for 90 days)
Trial: 10562113
Drug: Advanced nurse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced nurse practitioner intervention in cardiovascular medicine
Trial: 8804228
Drug: Vasoactive agents
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoactive agents (dopamine)
Trial: 1832181
Drug: Antacids and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacids and H2-antagonists
Trial: 6859790
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hydrochlorothiazide and metoprolol
Trial: 26550687
Drug: Fluticasone furoate/vilanterol
RxNorm normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/vilanterol 100/25 μg
Trial: 25155600
Drug: Eltrombopag (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag (200 mg single dose)
Trial: 25155600
Drug: Boceprevir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boceprevir (800 mg every 8 hours for 10 days)
Trial: 25155600
Drug: Telaprevir (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telaprevir (750 mg every 8 hours for 10 days)
Trial: 25155600
Drug: Eltrombopag (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag (200 mg single dose with boceprevir or telaprevir)
Trial: 20511481
Drug: Gabapentin enacarbil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin enacarbil, 1200 mg
Trial: 18794746
Drug: Individualized physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized physical therapy and exercise, standardized self-training program, and back education
Trial: 18794746
Drug: Self-training program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-training program and back education (no individualized therapy)
Trial: 12271286
Drug: Topical imiquimod
RxNorm normalized name: imiquimod Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical imiquimod 5% cream, applied 3 times a week for up to 16 weeks
Trial: 7852871
Drug: Purified fibrinogen
RxNorm normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified fibrinogen from insulin-dependent diabetics
Trial: 24947106
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of responsive stimulation and enhanced nutrition
Trial: 23673269
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 (PGE2) infusion
Trial: 23673269
Drug: EP4 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP4 receptor antagonist BGC20‐1531
Trial: 23673269
Drug: Prostaglandin F2α
RxNorm normalized name: 15(S)-15-Methyl Prostaglandin F2α
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin F2α (PGF2α) infusion
Trial: 20827017
Drug: Hydrocortisone aceponate
RxNorm normalized name: HYDROCORTISONE ACEPONATE
DrugBank: Hydrocortisone aceponate (DB14538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone aceponate (0.127%) lipophilic cream applied twice daily
Trial: 18221398
Drug: GHRH +
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH + ARG (1 microg/kg body weight i.v. GHRH followed by 0.5 g/kg body weight i.v. arginine hydrochloride)
Trial: 12513038
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate daily
Trial: 9204355
Drug: Iopentol (Imagopaque
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopentol (Imagopaque 250 mg I/ml)
Trial: 9204355
Drug: Diatrizoate (Urografin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diatrizoate (Urografin 219 mg I/ml)
Trial: 8201703
Drug: Intraarterial thrombolytic
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial thrombolytic therapy (urokinase)
Trial: 2444000
Drug: Cefazolin (CFZ)
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin (CFZ) 4 days (16 X 0.5 g)
Trial: 2444000
Drug: Cefuroxime (CFX)
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime (CFX) 2 days (4 X 1.5 g)
Trial: 2444000
Drug: Cefazolin (CFZ)
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin (CFZ) 1 day (4 X 0.5 g)
Trial: 1146747
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives with vitamin B6 deficiency
Trial: 30396006
Drug: Barley beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barley beta glucans (6 g in experimental bread)
Trial: 3071871
Drug: Endoscopic haemostatic
RxNorm normalized name: collagen hemostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic haemostatic injection with absolute alcohol (Asaki's method)
Trial: 2651100
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (blood transfusions, antacids, cimetidine, pirenzepine)
Trial: 27922030
Drug: Famotidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (40 mg, before bedtime)
Trial: 25524481
Drug: Low viscosity
RxNorm normalized name: Gentamicin low viscosity bone cement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low viscosity bone cement (group L)
Trial: 22803642
Drug: TAK-683 (0.01-2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-683 (0.01-2.0 mg)
Trial: 22803642
Drug: TAK-683 (0.03-1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-683 (0.03-1.0 mg on day 1, followed by 0.01-2.0 mg continuous infusion on days 2-13)
Trial: 22803642
Drug: TAK-683 (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-683 (2.0 mg day(-1) continuous dosing)
Trial: 22803642
Drug: TAK-683 continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-683 continuous dosing
Trial: 16447105
Drug: Gentamicin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (2.5 mg/kg intramuscularly every 12 h for 7 days)
Trial: 16447105
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg orally for adults and 2.2 mg/kg orally for children every 12 h for 7 days)
Trial: 1738926
Drug: ALG (Merieux)
RxNorm normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALG (Merieux) until serum creatinine was less than 300 mumol/L
Trial: 1738926
Drug: Steroid-sensitive rejection
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-sensitive rejection